In the phase III trial, which was stopped early, Entresto proved superior to the ACE inhibitor enalapril, reducing the risk of cardiovascular death or heart failure hospitalisation by 20 per cent ...

All told, Entresto-treated patients were 46% less likely to die, be re-admitted to hospital with heart failure, need a left ventricular assist device (LVAD), or be put on a waiting list for heart ...

On the other hand, Enalapril is used to treat high blood pressure and heart failure (the weakening of heart function). Amlodipine works by relaxing blood vessels, allowing blood to flow more ...